(Burlingame,
CA) Walk away automation, is how Halo Labs’
device is placed on the marquee. The
actual device is named, Horizon.
Currently, Horizon is designed and manufactured, so that, it has a large
particle screen. Additionally, this
device’s operations are similar to a video game. For example, writing command line code to
program a liquid handler, is an automated process. When it is in use in the laboratory, Horizon
becomes, a laboratory instrument. As a
laboratory instrument, it is considered to be the industry’s first system. Horizon; as the first system that is designed
to specifically address the demand for quantitative subvisible particle
analysis, does work at every stage of the biologic drug formulation
process. Being more exact about the
previously said; obviously. Recently,
Halo Labs announced that, it is firmly committed to its Horizon. Specifically, the aforementioned business
revealed that, it has secured $12 million USD in a Series B funding round. As part of the funding round, individual
people invested. The individual people
are Paul McEwan and current Halo Labs employees. The most noteworthy new investors of the
aforementioned business are Research Corporation Technologies (RCT), Broad Oak
Capital Partners and Bio Advance.
Bio Advance, Broad Oak Capital
Partners and Research Corporation Technologies (RCT) as the most noteworthy new
investors; will be contributing funds.
The funds will be used for the following two things. The two things are expansion and acquisition. In reference to, expansion, the aforementioned
is for the sales department.
Specifically, Halo Labs intends to use the funds to expand the worldwide
sales presence, of the business. In
reference to, acquisition, the aforementioned is to expand Halo Labs’
next-generation product portfolio. In
other words; Halo Labs, is going to actively seek complementary technologies,
and, businesses. The goal of the
acquisition, is to be able to, expand into the analytical particle space.
However and returning to, Horizon,
the aforementioned device is capable of true low volume high throughput
subvisible particle analysis. The
previous, is how particle screening is performed. This is done; early on as lead optimization,
and, pre-formulation testing. Therefore,
hundreds of conditions can be analyzed.
This allows scientists to gain key insights, into, a drug’s
stability. This ability reduces
developmental risk, and, time to market.
A proprietary background membrane imaging (B.M.I.) technology, is the
power source of, Halo Labs’ Horizon. As
a result; Horizon is set apart by the fact that, it can run 200 stability test
samples in less than one day. The
previously said, can be done with only 25 µL per test. After this point, this device automatically
analyzes the data. The data results, are
presented as pictures and images.
Chad Souvignier is the Vice
President of Research Corporation Technologies. Through a press statement, Mr. Souvignier said
the following. “Horizon is crucial at
every stage of biologic drug formulation.
In early stages, it can reveal SVP formation missed by other techniques
such as light obscuration and flow imaging.
In later stages, it can differentiate proteins from extrinsic particles
such as glass and plastic. And given the
experience of the Halo Labs management team in product development and Sales,
we are eager to find other technologies that we can help bring to market.”
To end, Halo Labs did release a
press statement. Robert Wicke is the
Chief Executive Officer of Halo Labs.
Through a press statement, Mr. Wicke said the following. “The success of Horizon, especially in the
Gene Therapy field, provides confirmation that next-generation product development
is critical. There is so much more this
technology can provide in a variety of markets.
One of our latest customers, the US FDA, will be using the product to
help understand the risks for patients on drug product manufacturing. This is a further indication that Horizon is
the product of choice for particle analysis in the subvisible range.” As previously stated, Halo Labs recently
announced that, it is firmly committed to its Horizon. Specifically, the aforementioned business
revealed that, it has secured $12 million USD in a Series B funding round. As part of the funding round, individual
people invested. The individual people
are Paul McEwan and current Halo Labs employees. Lastly; the most noteworthy new investors of
the aforementioned business are Research Corporation Technologies (RCT), Broad
Oak Capital Partners and Bio Advance.
###
Written
from Press Release
Registered
Writer with
PR
Newswire Association, LLC
R-Berumen28
04/10/2020
Post a Comment